ERBB2 and cancer: Taken together, we demonstrate that LARP6 serves as a dual regulator of proliferation and immune infiltration of TNBC cells instead of ER+ and HER2+ cancer cells, suggesting its potential to be the specific therapeutic target for the aggressive TNBC subtype.